To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Sip, don't gulp
The net effect is increased production plus slower removal, a twofold push toward symptoms
You receive a personalized plan, possible GLP-1 treatment if appropriate, and ongoing coachingwithout leaving home
Participants received 30 or 60 mg/day of Q10 for 100 days, and serum samples were analyzed for Q10 concentrations, malondialdehyde, total antioxidant status, SOD, and glutathione peroxidase, using ELISA assays
While treatment often involves exercise, a healthy diet, and other lifestyle changes, medications may also be prescribed to help